David Bright1, Marcia Worley2, Brianne L Porter3. 1. Department of Pharmaceutical Sciences, Ferris State University College of Pharmacy, 220 Ferris Dr. Big Rapids, MI, 49307, USA. Electronic address: davidbright@ferris.edu. 2. The Ohio State University College of Pharmacy, USA; Division of Outcomes and Translational Sciences, College of Pharmacy, A214 Parks Hall, 500 W. 12th Avenue, Columbus, OH, 43210, USA. Electronic address: worley.18@osu.edu. 3. The Ohio State University College of Pharmacy, USA; Division of Pharmacy Education and Innovation, A208 Parks Hall, 500 W. 12th Ave., Columbus, OH, 43210, USA. Electronic address: porter.618@osu.edu.
Abstract
BACKGROUND: In order to optimize community pharmacist roles and patient outcomes, a better understanding of patient perceptions of pharmacogenomic (PGx) testing may be helpful for successful integration into community pharmacy practice. OBJECTIVE: The objective of this study was to identify patient perceptions related to PGx testing in the community pharmacy setting. METHODS: Semi-structured, face-to-face interviews were conducted with adults ≥18 years of age to gather their perceptions of PGx testing. Interview participants were taking either an antiplatelet agent or a selective serotonin reuptake inhibitor listed in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and were patients at one of two community pharmacies in West Michigan. Interview questions were designed to follow the Theory of Planned Behavior and to take into account existing literature on patient perceptions of PGx. Interviews were recorded, transcribed by a third party transcription service, coded by a team of three researchers to identify themes, and analyzed using nVivo qualitative analysis software. RESULTS: A total of 19 interviews were conducted over a period of 16 days in June 2016. Upon preliminary evaluation, four themes related to patient perceptions of PGx testing were consistently observed across multiple interviews: 1) trust, 2) experience, 3) risk/benefit, and 4) clarity. CONCLUSIONS: Semi-structured patient interviews revealed four themes related to PGx testing in the community pharmacy setting. These themes may influence the desire to pursue PGx testing. Future research may seek to identify how community pharmacists can communicate with patients about PGx in the context of these themes to empower patients to make positive health care decisions.
BACKGROUND: In order to optimize community pharmacist roles and patient outcomes, a better understanding of patient perceptions of pharmacogenomic (PGx) testing may be helpful for successful integration into community pharmacy practice. OBJECTIVE: The objective of this study was to identify patient perceptions related to PGx testing in the community pharmacy setting. METHODS: Semi-structured, face-to-face interviews were conducted with adults ≥18 years of age to gather their perceptions of PGx testing. Interview participants were taking either an antiplatelet agent or a selective serotonin reuptake inhibitor listed in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and were patients at one of two community pharmacies in West Michigan. Interview questions were designed to follow the Theory of Planned Behavior and to take into account existing literature on patient perceptions of PGx. Interviews were recorded, transcribed by a third party transcription service, coded by a team of three researchers to identify themes, and analyzed using nVivo qualitative analysis software. RESULTS: A total of 19 interviews were conducted over a period of 16 days in June 2016. Upon preliminary evaluation, four themes related to patient perceptions of PGx testing were consistently observed across multiple interviews: 1) trust, 2) experience, 3) risk/benefit, and 4) clarity. CONCLUSIONS: Semi-structured patient interviews revealed four themes related to PGx testing in the community pharmacy setting. These themes may influence the desire to pursue PGx testing. Future research may seek to identify how community pharmacists can communicate with patients about PGx in the context of these themes to empower patients to make positive health care decisions.
Authors: Pablo Zubiaur; David Nicolás Prósper-Cuesta; Jesús Novalbos; Gina Mejía-Abril; Marcos Navares-Gómez; Gonzalo Villapalos-García; Paula Soria-Chacartegui; Francisco Abad-Santos Journal: J Pers Med Date: 2022-02-12